Here, we describe the findings from the preclinical companion study to the NCI-MPACT clinical trial and demonstrate the value of using the well characterized NCI PDMR models to support interpretation of precision oncology studies, and of assigning treatment with temozolomide-based regimens dependent on MGMT deficiency across a spectrum of tumor histologies. This evidence concerns the gene MGMT and neoplasm.